Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 ...

Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib ... types in clinical trials and has broad franchise potential. In clinical trials ...

Read more about ARS Pharma, honored as No. 34 on Fast Company’s list of the World ... Lilly has also continued to build on its lucrative GLP-1 franchise of Mounjaro and Zepbound.

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Alnylam Pharmaceuticals saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's ... transform the TTR franchise, significantly ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3 ... across multiple tumor types in clinical trials and has broad franchise potential. In ...

That’s one way that Chiesi Group – an Italian family business-turned-global pharma ... franchise, told pharmaphorum. “It's really embedded into the core decision-making of the company ...